Catalent Reports Strong Q4 Results Amid Pending Acquisition by Novo Holdings

Revenue Growth:
Catalent reported a 23% increase in net revenue for Q4 2024, reaching $1.30 billion, and a 24% increase in constant currency.

Segment Performance:
The Biologics segment saw a 51.3% year-over-year revenue increase, while the Pharma and Consumer Health (PCH) segment increased by 6.4%.

Adjusted EBITDA:
Adjusted EBITDA for Q4 2024 more than doubled to $305 million, with a margin of 23%, up from 12% in the same period last year.

Full-Year Performance:
For fiscal year 2024, Catalent reported net revenue of $4.38 billion, a 3% increase from fiscal 2023, but posted a net loss of $1.04 billion due to goodwill impairment charges.

Acquisition Update:
The company is awaiting the completion of its acquisition by Novo Holdings in a $16.5 billion deal, expected to close by the end of 2024, pending regulatory approvals.

Financial Health:
Catalent ended fiscal 2024 with cash and cash equivalents of $289 million and total debt of $4.91 billion, with a net leverage ratio of 6.6x, down from 9.3x as of March 31, 2024.